Rapid Diagnostics to Enhance Therapy Selection for the Treatment of Bacterial Infections

Ryu, HaYoung; Azim, Ahmed Abdul; Bhatt, Pinki J.; Uprety, Priyanka; Mohayya, Sana; Dixit, Deepali; Kirn, T.; Narayanan, Navaneeth

doi:10.1007/s40495-023-00323-1

Cited by 4 publications

(1 citation statement)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The evolution of resistant strains is largely caused by the overuse and misuse of antibiotics, which gets worse with self-medication, insufficient treatment regimens, and improper prescribing practices ( Nabaweesi et al, 2021 ). Furthermore, delayed targeted treatment and the spread of resistant variations are caused by empirical therapies, the inability to quickly identify specific bacterial strains, and the lack of point-of-care tests as well as rapid diagnostics ( Singh et al, 2021 ; Ryu et al, 2023 ). Biofilm infections continue to be a major concern in healthcare services because they are extremely resistant to antibiotics.…”

Section: Challenges In Addressing Amr and Prevalence Of Mdr/xdr And S...mentioning

confidence: 99%

Extensively and multidrug-resistant bacterial strains: case studies of antibiotics resistance

Almutairy

2024

Front. Microbiol.

View full text Add to dashboard Cite

The development of antibiotic resistance compromises the effectiveness of our most effective defenses against bacterial infections, presenting a threat to global health. To date, a large number of research articles exist in the literature describing the case reports associated with extensively drug-resistant (XDR) and multidrug-resistant (MDR) bacterial strains. However, these findings are scattered, making it time-consuming for researchers to locate promising results and there remains a need for a comparative study to compile these case reports from various geographical regions including the Kingdom of Saudi Arabia. Additionally, no study has yet been published that compares the genetic variations and case reports of MDR and XDR strains identified from Saudi Arabia, the Middle East, Central Europe, and Asian countries. This study attempts to provide a comparative analysis of several MDR and XDR case reports from Saudi Arabia alongside other countries. Furthermore, the purpose of this work is to demonstrate the genetic variations in the genes underlying the resistance mechanisms seen in MDR and XDR bacterial strains that have been reported in Saudi Arabia and other countries. To cover the gap, this comprehensive review explores the complex trends in antibiotic resistance and the growing risk posed by superbugs. We provide context on the concerning spread of drug-resistant bacteria by analyzing the fundamental mechanisms of antibiotic resistance and looking into individual case reports. In this article, we compiled various cases and stories associated with XDR and MDR strains from Saudi Arabia and various other countries including China, Egypt, India, Poland, Pakistan, and Taiwan. This review will serve as basis for highlighting the growing threat of MDR, XDR bacterial strains in Saudi Arabia, and poses the urgent need for national action plans, stewardship programs, preventive measures, and novel antibiotics research in the Kingdom.

show abstract

Section: Challenges In Addressing Amr and Prevalence Of Mdr/xdr And S...mentioning

confidence: 99%

Extensively and multidrug-resistant bacterial strains: case studies of antibiotics resistance

Almutairy

2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

Antibody-based therapy: An alternative for antimicrobial treatment in the post-antibiotic era

Luo,

Li,

Xing

et al. 2025

Microbiological Research

View full text Add to dashboard Cite

New Agents Are Coming, and So Is the Resistance

Keck,

Viteri,

Schultz

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Antimicrobial resistance is a global threat that requires urgent attention to slow the spread of resistant pathogens. The United States Centers for Disease Control and Prevention (CDC) has emphasized clinician-driven antimicrobial stewardship approaches including the reporting and proper documentation of antimicrobial usage and resistance. Additional efforts have targeted the development of new antimicrobial agents, but narrow profit margins have hindered manufacturers from investing in novel antimicrobials for clinical use and therefore the production of new antibiotics has decreased. In order to combat this, both antimicrobial drug discovery processes and healthcare reimbursement programs must be improved. Without action, this poses a high probability to culminate in a deadly post-antibiotic era. This review will highlight some of the global health challenges faced both today and in the future. Furthermore, the new Infectious Diseases Society of America (IDSA) guidelines for resistant Gram-negative pathogens will be discussed. This includes new antimicrobial agents which have gained or are likely to gain FDA approval. Emphasis will be placed on which human pathogens each of these agents cover, as well as how these new agents could be utilized in clinical practice.

show abstract

Rapid Diagnostics to Enhance Therapy Selection for the Treatment of Bacterial Infections

Cited by 4 publications

References 97 publications

Extensively and multidrug-resistant bacterial strains: case studies of antibiotics resistance

Extensively and multidrug-resistant bacterial strains: case studies of antibiotics resistance

Antibody-based therapy: An alternative for antimicrobial treatment in the post-antibiotic era

New Agents Are Coming, and So Is the Resistance

Contact Info

Product

Resources

About